This Houston expert describes the main phases central to any innovation journey. Photo courtesy of Slalom

As a technologist, one thing I learned early in my career about the technology landscape is its constant improvements and I understood that companies who kept up with those changes remain successful and competitive. However, only companies mastering a disciplined innovation framework are truly able to harness the power of emerging tech to help them solve their most complex business challenges.

Innovative solutions come in all shapes and sizes, but not all of them should come to life. Specifically, when considering digital solutions, there are a few widely accepted innovation approaches in the product engineering field. This quick guide describes the main phases central to any innovation journey.

Feasibility Study

Ideating can be fun but executing a feasibility study will ground you on what will work and what may still be science fiction. The thought here is to spend two to four weeks doing research and talking to experts to answer a few key questions that will help you determine the feasibility of your idea or concept. Through the study, you will learn how to look at it from both a technology and a business perspective. More importantly, to answer the question 'Is it even possible to accomplish your goal with this technology?'

A subject matter expert (SME) will quickly tell you yes or no and why. If you find the technology is indeed suitable, then you will move on to evaluate the business feasibility. Does it make financial sense? Does it work within established business policies? Will there be a healthy Return On Investment (ROI) within an acceptable timeline? If you find positive responses to those questions, then you should feel confident to move on to a Proof of Concept (PoC) or even jump to a Minimum Viable Product (MVP). On the other hand, if either the technology is not feasible or the solution doesn't make business sense, then you've just saved yourself a lot of time, budget, and possibly headaches.

Proof of Concept

This phase is about testing the theory and proving the hypothesis, technically speaking. You'll need to go through a Proof of Concept if the technology solution you have in mind hasn't been tested in either a lab setting or in the field. Thinking outside of the box and innovating is all about trying new approaches and solving problems in a novel way, so you'll have to spend the time and budget ensuring it will work as expected. However, you must be very careful to not get carried away.

A proper PoC should take four to six weeks, max. It should help you quickly determine whether the technology will live up to its promise or if you need to pivot to another approach. Building a team with the right skillset is vital to this process because they are the ones evaluating the proposed solution and comparing it to the expected outcomes. Any signs of discord should empower the team to stop the project, saving further investment, and should help you decide if another approach is even possible. If all criteria has been met, then move on to the MVP stage.

Minimum Viable Product

At this point, you have confirmed the solution you imagined works and you are ready to unlock its potential. But you must start small. You must prioritize all the features you want this product to have and decide what the core functionality should be. This is important because if you choose too many features to start with, you may initially spend too much money and time and may even miss a window of business opportunity you may have lined up. Hence the name of the MVP, it is a product that employs the minimum time, money, and features while still being a viable product.

In summary, if you have an innovative idea for a technology solution, I recommend you first determine whether it's feasible, both technology and business wise, through a short and focused study. If feasible, then you can put that concept to the test through a PoC and determine its desirability. If this product is indeed desirable, then moving into building an MVP will help you understand its viability – and that is how you can successfully innovate while keeping risks at bay.


------

Alfredo Arvide is the director for the products and innovation practice at Slalom Consulting in Houston, where he helps clients solve their most complex business challenges by leveraging emerging technologies and applying innovative technology solutions.

This week's roundup of Houston innovators includes Alfredo Arvide of Slalom Consulting, Allison Post of the Texas Heart Institute, and Jeff Price of Pronto Pay. Courtesy photos

3 Houston innovators to know this week

who's who

Editor's note: In this week's roundup of Houston innovators to know, I'm introducing you to three local innovators across industries — tech consulting, health care, and fintech — recently making headlines in Houston innovation.

Alfredo Arvide, senior principal within product engineering at Slalom Consulting

Should you launch an app? Or just a web page? This consultant weighs in with his advice. Photo courtesy of Slalom

Tech founders have a lot of decisions to make, and Alfredo Arvide of Slalom Consulting wrote a guest column for InnovationMap to help advise on a big one.

"One of the biggest decisions you'll have to make as an entrepreneur is whether you should host your product or service on the web, via an app, or through a webapp," he writes. "Product development has a million intricacies that will dictate – and sometimes demand – a specific route to market." Read more.

Allison Post, manager of innovation partnerships at the Texas Heart Institute

Allison Post joins the Houston Innovators Podcast to share what she's focused on in cardiac innovation. Photo courtesy of THI

In a perfect world, Houston's health care institutions work collaboratively on innovative health care solutions and the city soars as a major hub for life science innovation. That perfect world is Allison Post's goal. As Texas Heart Institute's manager of innovation partnerships, she is in charge of supporting THI innovators and connecting the institute with the rest of the city.

"I only see just phenomenal things for Houston, and what I really want is for the Texas Medical Center to become even more interconnected. We've got to be able to transfer ideas and thoughts and intentions seamlessly between these institutions and right now there are a lot of barriers," Post says. "And I really think Texas Heart is hopefully going to serve as an example of how to take down those barriers." Read more and stream the episode.

Jeff Price, founder and CEO of Pronto Pay

This Houston startup has an app for helping employees get a portion of their paychecks before payday. Photo via Pexels

So much of the country lives paycheck to paycheck, and Jeff Price saw a business opportunity to help out employees who need an advance on their wages. He founded Pronto Pay in the first quarter of 2021. The software aims to connect hourly works with transparent access to wages earned before pay day without disrupting the employers' books.

"When you think about it, payroll hasn't changed in nearly two centuries. As far as we can remember, you get paid weekly or bi-weekly. And that's precisely the point we're trying to solve," Price says. Read more.

Should you launch an app? Or just a web page? This consultant weighs in with his advice. Photo courtesy of Slalom

Web page or app? Houston expert shares his tips for launching your online platform

guest column

One of the biggest decisions you'll have to make as an entrepreneur is whether you should host your product or service on the web, via an app, or through a webapp. In this quick guide, I'll go over a few tips to help you narrow down the options and make an informed decision.

First, allow me to explain each of these terms. In this context, I am assuming your big idea is either a product or service which your customer base will consume in a digital format. The question is, do you deliver your product or service via a regular webpage (web), does it require robust native application functionality (app), or can it be a hybrid model where the app runs on browser (webapp).

Certainly, if you can sell your product or services through a simple online store, then the debate is over: you should just web. If you are just selling a new gadget, for example, you don't need an app nor a webapp. E-Commerce has come such a long way that a simple webpage will suffice.

However, if that is not your situation, then here's three main considerations to help you decide between building an app or a webapp.

Native hardware required

If your product or service will use a hardware component from your audience's mobile device or tablet, such as the GPS, the Camera, the Microphone, or the Gyroscope, then you should heavily lean towards building a native app.

There are web frameworks that will allow you to gain access to a devices' camera or GPS via a webapp, but none are as stable, reliable, or robust as using a native app framework.

The question then becomes, what operating system do you develop your native app in: Apple's iOS, Google's Android, Microsoft's Windows, other or all of them?

Keep in mind there are platforms – such as Xamarin – that enable you to develop in multiple native app ecosystems simultaneously, however, deciding the platform(s) will affect your timeline, budget and audience reach. Also know that if your product or service can or should be accessible offline, then that reinforces your native app decision and eliminates a webapp given they require connectivity to run on a browser.

Universal adoption expected

In contrast, if you are looking to sign-up a broad audience then you should lean towards building a webapp.

All devices, whether mobile, tablets or laptops, have sophisticated and modern web browsers that can easily run webapps. Therefore, if you don't want to worry about deciding between different platforms, then by building a universal webapp that is compatible with all popular browsers all your users will have immediate access.

This route also bypasses all the requirements you must meet and the policies you must comply with to publish your native app to communities such as Apple's App Store or Google Play.

Even better you can update and maintain your webapp at your own pace, not having to rely on Apple's or Google's approval and publish/update schedules.

Investment tolerance 

Now, if you gathered major seed funding or hit it big in a series A round giving you a higher upfront investment tolerance, then I'd advise you to go the native app route.

The aforementioned Apple and Google native app marketplaces, albeit strict, offer amazing features that you would not be able to leverage going the webapp route. Your customer experience will almost certainly be higher going native app, which will increase your ROI, promote repeat subscribers and overall success.

But this route will be more expensive than webapp, especially if you do decide to offer it on multiple major platforms. Hence, if you have the budget, go for it and launch natively. If your investment tolerance is more reserved, then start with a webapp, and simply iterate until you are forced to go native.

Table Description automatically generated

This quick guide is by no means an exhaustive list of considerations. Product development has a million intricacies that will dictate – and sometimes demand – a specific route to market. Yet, if you ask yourself a few of the questions I laid out, you will be able to make an informed decision guiding your commercialization strategy as you kick off your startup journey.

------

Alfredo Arvide is a senior principal within product engineering at Slalom Consulting in Houston, where he helps clients tackle their most complex business challenges by applying innovative technology solutions.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Intuitive Machines forms partnership with Italian companies for lunar exploration services

to the moon

Houston-based space technology, infrastructure and services company Intuitive Machines has forged a partnership with two Italian companies to offer infrastructure, communication and navigation services for exploration of the moon.

Intuitive Machines’ agreement with the two companies, Leonardo and Telespazio, paves the way for collaboration on satellite services for NASA, a customer of Intuitive Machines, and the European Space Agency, a customer of Leonardo and Telespazio. Leonardo, an aerospace, defense and security company, is the majority owner of Telespazio, a provider of satellite technology and services.

“Resilient, secure, and scalable space infrastructure and space data networks are vital to customers who want to push farther on the lunar surface and beyond to Mars,” Steve Altemus, co-founder and CEO of Intuitive Machine, said in a news release.

Massimo Claudio Comparini, managing director of Leonardo’s space division, added that the partnership with Intuitive Machines is a big step toward enabling human and robotic missions from the U.S., Europe and other places “to access a robust communications network and high-precision navigation services while operating in the lunar environment.”

Intuitive Machines recently expanded its Houston Spaceport facilities to ramp up in-house production of satellites. The company’s first satellite will launch with its upcoming IM‑3 lunar mission.

Intuitive Machines says it ultimately wants to establish a “center of space excellence” at Houston Spaceport to support missions to the moon, Mars and the region between Earth and the moon.

Houston hospitals win $50M grant for ibogaine addiction treatment research

ibogaine funding

The Texas Health and Human Services Commission has awarded $50 million to UTHealth Houston in collaboration with The University of Texas Medical Branch at Galveston (UTMB Health) to co-lead a multicenter research trial to evaluate the effect of ibogaine, a powerful psychoactive compound, on patients suffering from addiction, traumatic brain injury and other behavioral health conditions.

The funding will establish a two-year initiative—known as Ibogaine Medicine for PTSD, Addiction, and Cognitive Trauma (IMPACT)—and a consortium of Texas health institutions focused on clinical trials and working toward potential FDA-approved treatments.

The consoritum will also include Texas Tech University, Texas Tech University Health Sciences Center El Paso, The University of Texas at Austin, The University of Texas Health Science Center at San Antonio, The University of Texas at Tyler, The University of Texas Rio Grande Valley, Texas A&M University, The University of North Texas Health Science Center, Baylor College of Medicine and JPS Health Network in Dallas.

Ibogaine is a plant-based, psychoactive substance derived from the iboga shrub. Research suggests that the substance could be used for potential treatment for patients with traumatic brain injuries, which is a leading cause of post-traumatic stress disorders. Ibogaine has also shown potential as a treatment for addiction and other neurological conditions.

UTHealth and partners will focus on ways that ibogaine can treat addiction and associated conditions. Meanwhile, UT Austin and Baylor College of Medicine will concentrate on using it to treat traumatic brain injury, especially in veterans, according to a news release from the institutions.

The consortium will also support drug developers and teaching hospitals to conduct FDA-approved clinical trials. The Texas Health and Human Services Commission will oversee the grant program.

“This landmark clinical trial reflects our unwavering commitment to advancing research that improves lives and delivers the highest standards of care,” Dr. Melina Kibbe, UTHealth Houston president and the Alkek-Williams Distinguished Chair, said in the news release. “By joining forces with outstanding partners across our state, we are building on Texas’ tradition of innovation to ensure patients struggling with addiction and behavioral health conditions have access to the best possible outcomes. Together, we are shaping discoveries that will serve Texans and set a model for the nation.”

The consortium was authorized by the passage of Senate Bill 2308. The bill provides $50 million in state-matching funds for an ibogaine clinical trial managed by a public university in partnership with a drug company and a hospital.

“This is the first major step towards the legislature’s goal of obtaining FDA approval through clinical trials of ibogaine — a potential breakthrough medication that has brought thousands of America’s war-fighters back from the darkest parts of depression, anxiety, PTSD, and chronic addiction,” Texas Rep. Cody Harris added in the release. “I am excited to walk alongside UTHealth Houston and UTMB as these stellar institutions lead the nation in a first-of-its-kind clinical trial in the U.S.”

Recently, the University of Houston also received a $2.6 million gift from the estate of Dr. William A. Gibson to support and expand its opioid addiction research, which includes the development of a fentanyl vaccine that could block the drug's ability to enter the brain. Read more here.

Tesla no longer world's biggest EV maker as sales fall for second year

Tesla Talk

Tesla lost its crown as the world’s bestselling electric vehicle maker as a customer revolt over Elon Musk’s right-wing politics, expiring U.S. tax breaks for buyers and stiff overseas competition pushed sales down for a second year in a row.

Tesla said that it delivered 1.64 million vehicles in 2025, down 9% from a year earlier.

Chinese rival BYD, which sold 2.26 million vehicles last year, is now the biggest EV maker.

It's a stunning reversal for a car company whose rise once seemed unstoppable as it overtook traditional automakers with far more resources and helped make Musk the world's richest man. The sales drop came despite President Donald Trump's marketing effort early last year when he called a press conference to praise Musk as a “patriot” in front of Teslas lined up on the White House driveway, then announced he would be buying one, bucking presidential precedent to not endorse private company products.

For the fourth quarter, Tesla sales totaled 418,227, falling short of even the much reduced 440,000 target that analysts recently polled by FactSet had expected. Sales were hit hard by the expiration of a $7,500 tax credit for electric vehicle purchases that was phased out by the Trump administration at the end of September.

Tesla stock fell 2.6% to $438.07 on Friday.

Even with multiple issues buffeting the company, investors are betting that Tesla CEO Musk can deliver on his ambitions to make Tesla a leader in robotaxi services and get consumers to embrace humanoid robots that can perform basic tasks in homes and offices. Reflecting that optimism, the stock finished 2025 with a gain of approximately 11%.

The latest quarter was the first with sales of stripped-down versions of the Model Y and Model 3 that Musk unveiled in early October as part of an effort to revive sales. The new Model Y costs just under $40,000 while customers can buy the cheaper Model 3 for under $37,000. Those versions are expected to help Tesla compete with Chinese models in Europe and Asia.

For fourth-quarter earnings coming out in late January, analysts are expecting the company to post a 3% drop in sales and a nearly 40% drop in earnings per share, according to FactSet. Analysts expect the downward trend in sales and profits to eventually reverse itself as 2026 rolls along.

Musk said earlier last year that a “major rebound” in sales was underway, but investors were unruffled when that didn't pan out, choosing instead to focus on Musk's pivot to different parts of business. He has has been saying the future of the company lies with its driverless robotaxis service, its energy storage business and building robots for the home and factory — and much less with car sales.

Tesla started rolling out its robotaxi service in Austin in June, first with safety monitors in the cars to take over in case of trouble, then testing without them. The company hopes to roll out the service in several cities this year.

To do that successfully, it needs to take on rival Waymo, which has been operating autonomous taxis for years and has far more customers. It also will also have to contend with regulatory challenges. The company is under several federal safety investigations and other probes. In California, Tesla is at risk of temporarily losing its license to sell cars in the state after a judge there ruled it had misled customers about their safety.

“Regulatory is going to be a big issue,” said Wedbush Securities analyst Dan Ives, a well-known bull on the stock. “We're dealing with people's lives.”

Still, Ives said he expects Tesla's autonomous offerings will soon overcome any setbacks.

Musk has said he hopes software updates to his cars will enable hundreds of thousands of Tesla vehicles to operate autonomously with zero human intervention by the end of this year. The company is also planning to begin production of its AI-powered Cybercab with no steering wheel or pedals in 2026.

To keep Musk focused on the company, Tesla’s directors awarded Musk a potentially enormous new pay package that shareholders backed at the annual meeting in November.

Musk scored another huge windfall two weeks ago when the Delaware Supreme Court reversed a decision that deprived him of a $55 billion pay package that Tesla doled out in 2018.

Musk could become the world's first trillionaire later this year when he sells shares of his rocket company SpaceX to the public for the first time in what analysts expect would be a blockbuster initial public offering.